Burns:天冬氨酸氨基转移酶/丙氨酸转氨酶(德里蒂斯比率)预测严重烧伤患者的存活率

2022-08-20 医路坦克 MedSci原创

大面积烧伤患者死亡风险的评估具有重要意义,血清天冬氨酸氨基转移酶与丙氨酸氨基转移酶水平之间的比率是许多疾病的不良预后的独立预测因子,本文评估其是否有助于评估大面积烧伤患者的预后。

尽管近几十年来烧伤患者的治疗有了很大的改善,但严重烧伤仍然是致命的。因此,对大面积烧伤患者死亡风险的评估具有重要意义。血清天冬氨酸氨基转移酶与丙氨酸氨基转移酶水平之间的比率(De Ritis比率)是急性缺血性卒中、心脏手术、非转移性肾细胞癌和上尿路尿路癌患者不良预后的独立预测因子。

我们的目的是确定血清AST和ALT水平之间的比值(De Ritis Ratio)是否有助于评估大面积烧伤患者的预后。

方法:我们在长海医院烧伤科进行了单中心队列研究。本次回顾性观察分析基于2005年5月1日至2018年4月30日收治的重大烧伤患者的临床资料。采用单因素和多因素Logistic回归分析影响大面积烧伤患者病死率的因素:年龄、性别、总体表面积(TBSA)、De Ritis比率和血清白蛋白水平。通过受试者工作特征(ROC)曲线分析,评价其诊断价值,找出诊断的临界值。我们使用Kaplan-Meier曲线来显示De Ritis比率和血清白蛋白水平对烧伤患者生存的影响。

结果:本研究共纳入351例大面积烧伤患者。队列主要由男性(74.64%)组成,大多数患者(78.35%)曾被火焰烧伤。年龄、TBSA、吸入和De Ritis比率是严重烧伤患者30天死亡率的独立危险因素,而年龄、TBSA、吸入和De Ritis比率是90天死亡率的独立危险因素。此外,在严重烧伤患者中,De Ritis比率是比血清白蛋白更好的死亡率预测因子,其30天和90天的ROC下面积分别为0.771(95%可信区间[CI],0.708-0.835)和0.750(95%可信区间[CI],0.683,0.818)。

比较DeRitis>1.855和DeRitis<1.855的患者的Kaplan-Meier生存曲线。

比较白蛋白>2.749 g/L与DeRitis<2.749 g/L患者的Kaplan?Meier生存曲线。

结论:De Ritis比率可作为大面积烧伤患者的预后指标,可通过血检方便地获得。不管预测的是30天还是90天的死亡率,准确率仍然很高。此外,与血清白蛋白水平相比,De Ritis比率在评估大面积烧伤患者的预后方面更具优势。

文献来源:Wang B,  Hu L,  Chen Y, Aspartate transaminase/alanine transaminase (De Ritis ratio) predicts survival in major burn patients.Burns 2022 Jun;48(4)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674629, encodeId=155316e462906, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Thu Jan 12 06:57:38 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752048, encodeId=dc691e520486e, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Dec 30 02:57:38 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863003, encodeId=d37b186300379, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat Oct 22 16:57:38 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395480, encodeId=d2d513954807a, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Aug 20 14:57:38 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674629, encodeId=155316e462906, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Thu Jan 12 06:57:38 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752048, encodeId=dc691e520486e, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Dec 30 02:57:38 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863003, encodeId=d37b186300379, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat Oct 22 16:57:38 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395480, encodeId=d2d513954807a, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Aug 20 14:57:38 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674629, encodeId=155316e462906, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Thu Jan 12 06:57:38 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752048, encodeId=dc691e520486e, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Dec 30 02:57:38 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863003, encodeId=d37b186300379, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat Oct 22 16:57:38 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395480, encodeId=d2d513954807a, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Aug 20 14:57:38 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674629, encodeId=155316e462906, content=<a href='/topic/show?id=255c6e146aa' target=_blank style='color:#2F92EE;'>#烧伤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67146, encryptionId=255c6e146aa, topicName=烧伤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b15f27034396, createdName=俅侠, createdTime=Thu Jan 12 06:57:38 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752048, encodeId=dc691e520486e, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Fri Dec 30 02:57:38 CST 2022, time=2022-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863003, encodeId=d37b186300379, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Sat Oct 22 16:57:38 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395480, encodeId=d2d513954807a, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Aug 20 14:57:38 CST 2022, time=2022-08-20, status=1, ipAttribution=)]

相关资讯

J INTERN MED:噬血细胞性淋巴组织细胞增生症的发病率和存活率

英格兰噬血细胞性淋巴组织细胞增生症的诊断在2000年至2016年期间有所增加。75岁以上和血液系统恶性肿瘤患者的一年生存率差异很大。

胸主动脉破裂患者腔内治疗存活率——来自全球腔内主动脉治疗注册表的结果

全球腔内主动脉治疗注册表是一个前瞻性、观察性、多中心队列注册表,登记了所有使用戈尔胸主动脉覆膜血管内支架系统(GORE TAG Thoracic Endoprosthesis)治疗的各种主动脉疾病。

Dig Liver Dis: 医疗环境与急性上消化道出血的存活率有关

目前关于医疗环境对急性上消化道出血患者的生存率影响的数据有限。本项研究旨在识别能为急性上消化道出血患者提供最佳生存的组织和护理环境。

Br J Cancer:白血病儿童患者的兄弟姐妹数量与存活率的相关性研究

白血病是全球大多数地区最常见的一种儿童期癌症。

Am J Clin Nutr:膳食蛋白质摄入量、肾功能和存活率:全国代表性队列研究

人们越来越关注膳食蛋白摄入量(DPI)作为慢性肾脏疾病(CKD)和非CKD人群健康和存活的重要调节因子。在普通人群中,摄入高膳食蛋白质饮食(如原始人饮食、阿特金斯饮食、生酮饮食)已被广泛推广,作为一种